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oi.orGraft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation is mediated by
the activation of recipient dendritic cells and subsequent proliferation of donor T cells. The complement sys-
tem was recently shown to modulate adaptive immunity through an interaction of the complement system
and lymphocytes. Complement proteins participate in the activation of dendritic cells, antigen presentation
to T cells, and proliferation of T cells. Our studies with a murine model of bonemarrow transplantation dem-
onstrate that complement system regulates alloimmune responses in GVHD. Mice deficient in the central
component of the complement system (C32/2) had significantly lower GVHD-related mortality and morbid-
ity compared with wild-type recipient mice. The numbers of donor-derived T cells, including IFN-g1, IL-171,
and IL-171IFN-g1 subsets, were decreased in secondary lymphoid organs of C32/2 recipients. Further-
more, the number of recipient CD8a1CD11c1 cells in lymphoid organs was reduced. We conclude that
C3 regulates Th1/17 differentiation in bone marrow transplantation, and define a novel function of the com-
plement system in GVHD.
Biol Blood Marrow Transplant 18: 1174-1181 (2012)  2012 American Society for Blood and Marrow Transplantation.
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Allogeneic bone marrow transplantation (allo-
BMT) is an effective therapy for hematologic malig-
nancies [1]. The limiting factor is graft-versus-host
disease GVHD, a result of alloimmune responses eli-
cited by donor T lymphocytes to major and minor an-
tigens [2-4]. GVHD is characterized primarily byion of Transplantation Immunology, Department of
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.00
g/10.1016/j.bbmt.2012.05.014targeted epithelial cell injury in skin, intestine, and
liver [4-6]. Although donor T lymphocytes and
recipient antigen-presenting cells (APCs) are the pri-
marily mediators of GVHD, the molecular and cellu-
lar bases of GVHD are not well understood. Over the
last decade, innate immunity has been shown to mod-
ulate adaptive immunity through the interaction
between the complement system and lymphocytes [7-
10]. The role of complement proteins in the cognate
interaction between alloreactive T cells and APCs
has been studied extensively in the setting of allograft
rejection [11-14]. These findings provide a new
opportunity to examine the role of the complement
system in alloimmune responses in GVHD.
The complement system, an important part of in-
nate immunity, includes several plasma and cell surface
proteins and is effective in killing invadingmicroorgan-
isms. Complement proteins are synthesized mainly in
the liver; however, local production of complement
proteins by APCs, lymphocytes, endothelium, and ep-
ithelial cells in the interstitial tissues plays an important
role in immunoregulation [7-10]. The complement
systems can be activated through 3 pathways: the
classic, alternative, and lectin pathways. Initiation
steps differ among these pathways, but all 3 pathways
Biol Blood Marrow Transplant 18:1174-1181, 2012 1175C3-Deficient Mice and GVHDconverge on the formation of a C3 convertase that is
essential for propagation of the complement cascade.
In the setting of allograft rejection, complement
proteins produced by dendritic cells (DCs) and non-
professional APCs residing in the allograft regulate
the alloactivation of CD41 and CD81 T cells
[11-16]. A seminal study found reduced rejection of
kidneys transplanted from C3-deficient donor mice
(C32/2) to wild-type (WT) mice [14]. Interestingly,
local extravascular C3 levels, but not plasma levels,
were the determinant of rejection, as evidenced by
the acute rejection of kidneys transplanted from WT
mice to C32/2 mice. Complement proteins are
involved in different stages of the interaction between
DCs and lymphocytes. C3 production by DCs is
essential for their maturation, differentiation, and
effective antigen presentation to T cells [17-20].
Complement proteins also have an autocrine effect
on APCs and T cells [15,19]. Moreover, T cells
secrete complement proteins, and C32/2 T cells
undergo more apoptosis than WT T cells [21]. Two
clinical entities that involve the interaction between
DCs and allogeneic T cells are solid organ trans-
plantation and allo-HSCT. Previous studies have
reported the deposition of complement proteins as
a major feature of murine acute GVHD [22], along
with increased morbidity and mortality associated
with murine cytomegalovirus infection after allo-
HSCT in mice deficient in decay accelerating factor
(a negative complement regulatory protein) [23]. In
the present study, we used C32/2 mice as recipients
in a murine model of BMT, and found that reduced
GVHD mortality and morbidity in C32/2 mice is as-
sociated with the decrease of donor Th1/Th17 differ-
entiation.MATERIALS AND METHODS
GVHD Induction
All recipients were age-matched females aged 2-6
months at the time of BMT. To generate BMT chi-
meras, recipient WT B6 or C32/2 mice (C57BL/6
background; Jackson Laboratory, BarHarbor,ME) re-
ceived 12 Gy of total body irradiation (137Cs source
split into 2 doses) on day 21 and 10  106 T cell–de-
pleted (TCD) bone marrow (BM) cells plus 15  106
splenocytes from BALB/c mice (National Cancer In-
stitute, Frederick,MD) on day 0 [24]. TheWT control
mice received only TCDBM cells and were monitored
for non–GVHD-associated mortality and morbidity.
Mice were monitored for clinical signs of GVHD (ie,
hair loss, hunched back, and diarrhea) and weighed
twice a week. For histopathological analysis of
GVHD target tissues, samples were collected from
skin, liver, intestine, lung, and kidney and fixed in
10% formalin. The tissue samples were embedded,sectioned, and stained with hematoxylin and eosin.
Tissue slides were graded by a pathologist according
to a published GVHD scoring system [25]. All animal
experiments were approved by the Institutional Ani-
mal Care and Use Committee at University of Texas
M.D. Anderson Cancer Center.
Statistical Analysis
Survival data and weight loss were plotted and an-
alyzed by a statistical analyst. To test for a differential
change between treatment groups, survival data were
plotted by the Kaplan-Meier method and analyzed us-
ing the log-rank test. A semiquantitative scale of 0-4
was used for histopathological changes by a patholo-
gist. Pathology scores were evaluated using Fisher’s
exact test. A P value of #.05 was considered statisti-
cally significant.
Analysis of Donor-Derived T Cells
The recipient mice were sacrificed at 7 days post-
transplantation. Spleen, peripheral and mesenteric
lymph nodes, and Peyer’s patches were harvested,
and single-cell suspensions were stained with CD3,
CD4, CD8, and H-2Dd antibodies. Donor-derived T
cells (H-2Dd1), CD41H-2Dd1 and CD81H-2Dd1
subsets, were collected and evaluated by fluorescent
activated cell sorting (FACS) analysis. The total num-
ber of cells of each subset recovered from tissues was
determined using FlowJo software (TreeStar, Ashland,
OR). IL-17– and IFN-g–producing cells were de-
termined as described previously [26]. In brief,
T cells were washed and restimulated with phorbol
12-myristate 13-acetate and ionomycin in the presence
of GolgiStop (BD Biosciences, San Jose, CA) for
5 hours, after which IL-17– and IFN-g–producing
cells were identified using intracellular staining, and
donor-derived T cells were determined using CD4
andH-2Dd antibodies by FACS analysis. The percent-
age of IL-171, IL-171IFN-g1, and IFN-g1 cells from
donor-derived CD41 cells (CD41H-2Dd1) was ana-
lyzed using FlowJo software.
Analysis of Recipient-Derived DCs
For DC collection, recipient mice were sacrificed
at 2 days posttransplantation. Spleen and lymph
nodes were harvested and then digested in 5 mL of
cIMDM with 250 mg/mL of collagenase B (Roche,
Indianapolis, IN) and 30 U/mL of DNase I (Sigma-
Aldrich, St Louis, MO) for 1 hour at 37C. Then
EDTA (5 mM final concentration) was added, and
the mixture was incubated on ice for 5 minutes. Single
cell suspensions were stained with CD80, CD86,
CD40, MHC-II, CD11c, and H-2Db antibodies and
analyzed by FACS. The mean fluorescence intensity
of the CD11c1H-2Db1 gated population was quanti-
fied for each surface molecule. To analyze DC subsets
1176 Biol Blood Marrow Transplant 18:1174-1181, 2012Q. Ma et al.in lymphoid organs, cells were stained with CD11c,
CD8a, and H-2Db antibodies. The percentages of
CD8a1 and CD8a2 DCs (CD11c1H-2Db1) were
determined by FACS analysis.RESULTS
WT B6 and C32/2 mice were lethally irradiated
and infused with BM cells and splenocytes from
BALB/c donors to induce GVHD [24]. C32/2 mice
had a significantly lower mortality rate and less weight
loss compared with WT recipients (Figure 1). Within
8 weeks posttransplantation, 75% of C32/2 recipients
survived, compared with only 20% of WT mice
(P5 .0008; n5 20 in each group).WhereasWT recip-Figure 1. GVHDmortality andmorbidity inWTand C32/2 recipient mice. (A
and splenocytes from Balb/c mice. The control were WT mice received only T
time to death were estimated using the Kaplan-Meier method, and groups wer
periments (5 mice/group/experiment) were summarized. P5 .0008; n5 20 for
a surrogate measure of GVHD. (C) Representative tissue sections fromGVHD
In WT mice (top panel), arrows indicate the histopathological changes in the
intestine (necrosis/apoptosis in the hyperplastic crypts), liver (lymphoplasmacy
and areas of focal necrosis of hepatocytes), and lung (thickened alveolar wall w
(lower panel), inflammatory cell infiltration was minimal with normal structure
scores of skin, intestine, liver, and lung in WTand C32/2 recipient mice. Resuients had severeGVHD in the skin, intestine, liver, and
lung (Figure 1C), C32/2 mice exhibited only mild
changes in these organs, reflected in their significantly
lower GVHD scores (Figure 1D).
Because donor T cell activation is a critical step in
the development of GVHD, we analyzed donor-
derived T cells in C32/2 mice at 7 days posttrans-
plantation. We found significantly lower numbers
of both CD41 and CD81 T cells in the spleen, lymph
nodes, and Peyer’s patches compared with WT re-
cipients (Figure 2A). The differentiation of effector
CD41 T helper (Th) cells is important in initiat-
ing mouse GVHD, which is considered a systemic
Th1-type response [27,28]. It was recently reported
that Th17 cells participate in GVHD pathogenesis) Lethally irradiatedWTor C32/2mice received TCD bonemarrow cells
CD BM cells. Survival was monitored daily for 8 weeks. Distributions of
e compared using the log-rank test. The results of four independent ex-
each group. (B) Average daily weight of recipientWTand C32/2mice as
organs on day 7 posttransplantation stained with hematoxylin and eosin.
skin (inflammatory cells infiltration and apoptotic cells in hair follicles),
tic infiltration of portal tracts, segmental loss of bile duct epithelial cells
ith inflammatory infiltration and necrotic cells). In C32/2 recipient mice
of skin, small intestine, liver, and alveoli in the lung. (D) Average GVHD
lts are shown as mean 6 SD (t test; n 5 3 in each group). *P\.05.
Figure 2. Donor-derived T cells in WTand C32/2 recipient mice. (A) Donor-derived T cells in the secondary lymphoid organs. Spleen, lymph nodes,
and Peyer’s patches were harvested from WTand C32/2 recipient mice on day 7 posttransplantation (n5 3 in each group from 3 independent exper-
iments). Cells recovered from these tissues were stained with CD3, CD4, CD8, and H-2Dd antibodies. The numbers of donor-derived T cells (H-2Dd1)
and CD41H-2Dd1 and CD81H-2Dd1 subsets were determined by FACS. (B-D) Donor-derived IL-17– and IFN-g–producing cells in WTand C32/2
recipient mice. Cells from spleen, mesenteric, and peripheral lymph nodes were collected from WT mice (n 5 4) and C32/2 mice (n 5 5) at 7 days
posttransplantation. Cells were stimulated with phorbol 12-myristate 13-acetate and ionomycin in the presence of Golgi-stop for 5 hours, and then
stained with CD4, IL-17, IFN-g, and H-2Dd antibodies. The percentage (B and C) and absolute number (D) of IL-171, IL-171IFN-g1, and IFN-g1 cells
from donor-derived CD41 cells (CD41H-2Dd1) was determined by FACS from 4 independent experiments. In (B) the data are representative contour
plots of intracellular IL-17 and IFN-g staining gated on CD41H-2Dd1 cells, and the quadrant gates were decided based on isotype controls. In (C) results
are shown as bar graphs representing mean 6 SD. P values were calculated using a t test comparing WTand C32/2 mice. *P\.05.
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regulate Th17 differentiation [29,30]. As shown in
Figure 2B and 2C, compared with WT mice, C32/2
mice had significantly lower percentages of donor-
derived IL-171 CD41 cells in the spleen (1.05% ver-
sus 3.5%), mesenteric lymph nodes (1.3% versus
3.1%), and peripheral lymph nodes (0.7% versus
1.53%). The same trend was seen for IFN-g1 and
IL-171IFN-g1 subsets of donor-derived CD41 cells.
C32/2 mice had lower percentages of IFN-g1 cells
in spleen (32.4% vs 45.2%), mesenteric lymph nodes(35% versus 50.45%) and peripheral lymph nodes
(33.7% versus 40.2%) and of IFN-g1 cells in spleen
(1.18% versus 0.8%), mesenteric lymph nodes
(7.88% versus 1.8%), and peripheral lymph nodes
(3.11% versus 1.7%), as well as lower absolute num-
bers of IL-17–, IL-17 and IFN-g–, and IFN-g–secret-
ing cells in the spleen and lymph nodes (Figure 2D).
Therefore, the Th1 and Th17 responses were signifi-
cantly reduced in C32/2 recipient mice.
To further assess the role of C3 in regulating Th1/
Th17 polarization during alloimmune responses, we
Figure 2. (Continued).
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cipient APCs in vitro [31]. Compared with WT mice,
C32/2 mice exhibited significant reductions in IFN-g
production and Tbet expression (Supplemental
Figure 1A) and also in Th17 production and RORgt
expression (Supplemental Figure 1B) in CD41 T cells
stimulated by APCs.
The activation of T cells is induced by APCs
in secondary lymphoid organs, including DCs, as pro-
fessional APCs [32-34]. The reduced surface
expression of costimulatory molecules on C32/2 DCs
contributes to their decreased capability in
allostimulation and decreased ability to reshape Th1/
2 responses in alloagrafts [7-9]. We collected
APCs from spleen and lymph nodes on day 2
posttransplantation. Measurement of cell surface
expression of CD80, CD86, CD40, and MHC class
II on recipient-derived APCs (CD11c1H-2Db1) by
FACS analysis revealed no significant decreases in cos-
timulatorymolecules andMHC II expression on APCs
from C32/2 mice compared with WT mice (data not
shown). Because the interaction between recipientDCs and donor T cells is one of the initial events in
GVHD, we further analyzed lymphoid DC subsets in
C32/2 recipient mice. Murine conventional DCs
(cDCs) in lymphoid organs include CD8a1 and
CD8a2 subsets, which have distinct functional proper-
ties, including IL-12 production and efficient antigen
cross-presentation [33,34]. As shown in Figure 3, com-
pared with WT mice, C32/2 mice had a significantly
lower percentage of recipient-derivedCD8a1CD11c1
cells in the spleen (0.32% versus 0.98%) and lymph no-
des (0.12% versus 1.68%) and well as lower absolute
numbers of these cells in the spleen (40,600 versus
117,700) and lymph nodes (250 versus 7740). These
findings indicate that C3 deficiency is associated with
a decrease in the CD8a1 cDC subset in lymphoid or-
gans posttransplantation. Furthermore, our finding of
a significant reduction in the CD8a1CD11c1 subset
in the spleen, lymph nodes, and bonemarrow of unma-
nipulated C32/2 mice compared to WT controls
(Supplemental Figure 2A and 2B) suggests that C3
might be required for the optimal generation and/or
maintenance of CD8a1 DCs in mice.
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Herein we report that complement plays a role in
GVHD. We found that C3 deficiency in recipient
mice can decrease GVHD mortality and morbidity,
and described the effect of C3 on Th1/Th17 differen-
tiation in the alloimmune response after BMT. The
development of GVHD is thought to involve 3 phases:
T cell activation, proliferation and differentiation of
allogeneic T cells into activated effector cells, and
finally specific tissue damage [6,28]. We have shown
that complement C3 in the recipient is important in
regulating donor Th1/Th17 differentiation (Figure 2),
and thus in determining the severity of GVHD
(Figure 1). Furthermore, we found reduced numbersFigure 3. Recipient-derived lymphoid DCs inWTand C32/2 recipient mice.
C32/2 (n5 5) recipient mice 2 days posttransplantation, and stained with CD1
DCs (CD11c1H-2Db1) were determined by FACS. (A) Percentage of recipien
contour plots of CD8a and CD11c expression gated on H-2Db1 cells. The q
shown as bar graphs representing mean 6 SD of 4 independent experimen
mice. *P\.05.of CD8a1CD11c1 cDCs in both posttransplant and
unmanipulated C32/2 mice, which likely accounts
for the decreased Th1/Th17 differentiation. Previous
studies have shown complement deposition in mouse
GVHD tissues [22] and demonstrated a link bet-
ween complement and experimental GVHD [23].
Using C32/2 mice, our results not only demonstrate
the critical role of C3 and the complement
pathway in GVHD, but also explore the molecular
and immunologic mechanism through which innate
immunity regulates alloimmune responses in GVHD.
The main effector cells in GVHD are T lympho-
cytes; however, their precise phenotype remains elu-
sive. Recent studies investigated CD41 T cell subsetsCells from spleen and lymph nodes were collected fromWT (n5 5) and
1c, CD8a, and H-2Db antibodies. The percentage of CD8a1 and CD8a2
t-derived CD8a1 DCs (CD11c1H-2Db1) shown in the representative
uadrant gates were determined based on isotype controls. (B) Results
ts. P values were calculated using a t test comparing WT and C32/2
1180 Biol Blood Marrow Transplant 18:1174-1181, 2012Q. Ma et al.as essential regulators of adaptive immune responses
and GVHD and found Th1/2/17 polarization regu-
lates GVHD in mice and humans [27]. The comple-
ment system is involved in CD41 T cell polarization
[7-9]. We found significantly reduced Th1 and Th17
responses in C32/2 recipient mice (Figure 2). Activa-
tion of donor CD41 T cells with recipient APCs
in vitro produced a more significant reduction in Th1
and Th17 responses when using C32/2 APCs com-
pared with using WT APCs (Supplemental Figure 1).
However, the bulk of the cytokine data were generated
using a pharmacologic stimulation method, and thus
conclusions relating to allospecificity of the Th1/
Th17 responses were not fully evaluated in this study.
Several previous studies have reported that the
recipient APCs, such as macrophages and DCs, play
a major role in the initiation of acute GVHD [35-39].
Given the emerging role of complement in DC
maturation and function in T cell alloactivation
[17-20], we investigated whether C3 regulates
recipient DCs and contributes to the pathogenesis of
GVHD. In contrast to the reported reduced surface
expression of costimulatory molecules on DCs from
C32/2 mice [18-20], we found that the surface
expressions of costimulatory molecules and MHC
class II on C32/2 DCs were similar to those from
WT recipients. It is possible that posttransplantation
alloactivation increased the expression of MHC II
and costimulatory molecules on WT and C32/2 DCs
to such a degree as to make the differences negligible.
Studies in C32/2 mice have shown that C3 pro-
duction by DCs is essential for their maturation, effec-
tive antigen presentation to T cells, and development
of Th1 response [9,15,20]. However, whether and
how C3 regulates each DC subset in the lymphoid
organs has not been characterized previously. We
analyzed DC subsets in the spleen and lymph nodes
of C32/2 mice, and found reduced numbers of
CD8a1CD11c1 cells in the secondary lymphoid
organs compared with WT recipients. In addition,
the reduction of CD8a1CD11c1 subset was also
observed in the unmanipulated C32/2 mice
compared with WT controls (Supplemental
Figure 2A and 2B). However, CD8a1CD11c1 cells
from C32/2 mice demonstrated no deficiency in IL-
12 production (Supplemental Figure 2C). Initial re-
ports indicated a role for CD8a1 DCs in the selective
stimulation of Th1 cells [40]. Moreover, recent studies
have shown that CD8a1 DCs are the major producer
of IL-12 and also have a unique ability to capture dead
cells and efficiently cross-present antigen [41]. It is
possible that the reduction of CD8a1 DCs in C32/2
recipient mice could contribute to decreased alloanti-
gen cross-presentation, reduced donor T cell activa-
tion, and GVHD protection.
We studied the role of the complement system in
GVHD using C3-deficient recipient mice, whichmeant using complement-deficient DCs. The main
reason that we chose this strategy is that DCs produce
1000 times more complement proteins than T cells,
and thus complement deficiency would be expected
to have a greater impact in DCs than in T cells [7-9].
However, T cells also produce complement
components (although at a fraction of the amount
expressed by DCs), as do various stromal and
parenchymal cells, including hepatic cells (the main
cellular source of complement in the circulation);
thus, complement components from several sources
may enhance complement interaction at the DC–T
cell interface.
In summary, we found significantly reduced
GVHD mortality and morbidity in C32/2 recipient
mice. The central step of the complement cascade
involves the cleavage of C3. Emerging data indicate
that immune cell–derived complement activation
plays an important physiological role in immune
regulation. Once the role of C3 in GVHD is estab-
lished, future work will need to address the impact
of and dissect the multiple mechanisms of comple-
ment’s contributions to alloimmune responses in
GVHD. Our findings reported here improve the un-
derstanding of molecular mechanisms of GVHD and
provide a rationale for the use of complement inhibi-
tors as potential therapeutic interventions for
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